Pharmacology News and Research

Latest Pharmacology News and Research

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will provide insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products at the World Generic Medicines Congress Americas, being held November 17 - 20, 2009 in Washington, DC.

From Parexel 18 Nov 2009

ScienceWorksForUS launched by the representatives of public and private research universities

Representatives of the nation's leading public and private research universities, joined by Speaker Nancy Pelosi and other Members of Congress, today announced the launch of ScienceWorksForUS, an initiative that will highlight the scientific research and related activities that have been made possible by the American Recovery and Reinvestment Act of 2009 (ARRA), also known as the stimulus.

18 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials.

From Parexel 17 Nov 2009

Consortium to define new modalities for treating hypertension and associated vascular complications

Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.

17 Nov 2009

Researchers discover a way to boost levels of palmitoylethanolamide

UC Irvine pharmacology researchers have discovered a way to boost levels of a natural body fat that helps decrease inflammation, pointing to possible new treatments for allergies, illnesses and injuries related to the immune system.

17 Nov 2009

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported its financial results for the quarter ended September 30, 2009.

16 Nov 2009

Priority Review of the NDA for intravenous acetaminophen extended by three months

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months.

15 Nov 2009

Detailed review findings of EMPOWER study to evaluate the Maestro System released

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced preliminary findings from its ongoing detailed review of its EMPOWER™ study, a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro® System in the treatment of obesity.

12 Nov 2009

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

Trinity Health to install Elsevier's online CDS solutions

Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.

10 Nov 2009

Dark side of compulsive eating

Researchers from Boston University School of Medicine (BUSM) have shown that intermittent access to foods rich in fat and sugar induces changes in the brain which are comparable to those observed in drug dependence. The findings, reported in the journal Proceedings of the National Academy of Sciences, may explain how abstinence from these foods contributes to relapse eating among dieters as well as related eating disorders.

10 Nov 2009

Three IVF attempts increase chances of a live birth

Just one in three women gives birth after a single IVF attempt, but the cumulative chance of a live birth increases with each cycle - where women are offered three cycles nearly two thirds go on to have babies, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg in Sweden.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

From Parexel 9 Nov 2009

Pharmacology News and Research

Latest Pharmacology News and Research

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products

ScienceWorksForUS launched by the representatives of public and private research universities

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials

Consortium to define new modalities for treating hypertension and associated vascular complications

Researchers discover a way to boost levels of palmitoylethanolamide

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

Priority Review of the NDA for intravenous acetaminophen extended by three months

Detailed review findings of EMPOWER study to evaluate the Maestro System released

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Trinity Health to install Elsevier's online CDS solutions

Dark side of compulsive eating

Three IVF attempts increase chances of a live birth

EpiCept announces third quarter 2009 financial results

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

Industry Focus - Biopharma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pharmacology News and Research

Latest Pharmacology News and Research

Industry Focus - Biopharma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in